Anticoagulant effect of sodium dehydroacetate (DHA-S) in rats

Journal of Applied Toxicology

Volumn 28, Issue 4, 2008, Pages 524-529

  Sakaguchi, Yuka ^a   Suga, Sachiko ^a   Oshida, Keiyu ^a   Miyamoto Kuramitsu, Keiko ^a   Ueda, Kohei ^a   Miyamoto, Yohei ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

Activated partial thromboplastin time (APTT); Hemorrhage; Hepaplastin test (HPT); Prolonged prothrombin time (PT); Rats; Sodium dehydroacetate (DHA S); Thrombo test (TTO); Vitamin K (VK); Vitamin K1 epoxide reductase (VKOR); Warfarin

Indexed keywords

DEHYDROACETIC ACID; FARNOQUINONE; PROTHROMBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THROMBOPLASTIN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; DRUG INHIBITION; ENZYME ACTIVITY; IN VITRO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOPLASTIN TIME; VITAMIN K DEFICIENCY;

ANIMALS; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FOOD ADDITIVES; HEMORRHAGE; LIVER; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRONES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VITAMIN K 2;

ANIMALIA; RATTUS;

EID: 44149107308     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1304     Document Type: Article

References (26)

1. Billeter M, Bollinger W, Martius C. 1964. Untersuchungen uber die Umwandlung von verfutterten K-vitaminen durch austausch der seitenkette und die rolle der darmbakterien hierbei. Biochem. Z. 340: 290-303.
2. Cain D, Hutson SM, Wallin R. 1998. Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. Thromb. Haemost. 80: 128-133.
3. Chan K, Lo AC, Yeung JH, Woo KS. 1995. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J. Pharm. Pharmacol. 47: 402-406.
4. Cosmetic Ingredient Review. 1985. Final report on the safety assessment of sodium dehydroacetate and dehydroacetic acid. J. Am. Coll. Toxicol. 4: 123-159.
5. Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, Locatelli F. 2001. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am. J. Kidney Dis. 38: 1009-1015.
6. Ishiwata H, Nishijima M, Fukasawa Y. 2001. Estimation of preservative concentration in foods and their daily intake based on official inspection results in Japan in fiscal year 1998. Shokuhin Eiseigaku Zasshi 42: 404-412.
7. Kanai K, Asada-Kubota M, Kanamura S. 1981. Morphological studies on the liver of mice administered with dehydroacetic acid. Kankyo Kagaku Sogo Kenkyujo Nenpo 8: 27-31.
8. Kurata M, Horii I. 2004. Blood coagulation tests in toxicological studies - review of methods and their significance for drug safety assessment. J. Toxicol. Sci. 29: 13-32.
9. Mammen EF. 1992. Coagulation abnormalities in liver disease. Hematol. Oncol. Clin. North Am. 6: 1247-1257.
10. Mosterd JJ, Thijssen HHW. 1991. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat. J. Pharmacol. Exp. Ther. 260: 1081-1085.
11. Motohara K, Endo F, Matsuda I. 1985. Effect of vitamin K administration on carboxy prothrombin (PIVKA-II) levels in newborns. Lancet 3: 242-244.
12. Ono K, Ono T, Matsumata T. 1995. The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clin. Nephrol. 43: 405-408.
13. Park BK. 1988. Warfarin: metabolism and mode of action: a review. Biochem. Pharmacol. 37: 19-27.
14. Prentice CR. 1985. Acquired coagulation disorders. Clin. Haematol. 14: 413-442.
15. Rehse K, Schinkel W, Siemann U. 1980. Anticoagulant 4-hydroxy-2-pyrones. Arch. Pharm. (Weinheim) 313: 344-351.
16. Roncaglioni MC, Reyers I, Cerletti C, Donati MB, De Gaetano G. 1988. Moderate anticoagulation by salicylate prevents thrombosis without bleeding complications. An experimental study in rats. Biochem. Pharmacol. 15: 4743-4745.
17. Sakamoto N, Kimura M, Hiraike H, Itokawa Y. 1996. Changes of phylloquinone and menaquinone-4 concentrations in rat liver after oral, intravenous and intraperitoneal administration. Int. J. Vitam. Nutr. Res. 66: 322-328.
18. Seevers MH, Shideman FE, Woods LA, Weeks JR, Kruse WT. 1950. Dehydroacetic acid (DHA). II. General pharmacology and mechanism of action. J. Pharmacol. Exp. Ther. 99: 69-83.
19. Shearer MJ. 1990. Annotation vitamin K and vitamin K-dependent proteins. Br. J. Haematol. 75: 156-162.
20. Spencer HC, Rowe VK, McCollister DD. 1950. Dehydroacetic acid (DHA). I. Acute and chronic toxicity. J. Pharmacol. Exp. Ther. 99: 57-68.
21. Sutcliffe FA, MacNicoll AD, Gibson GG. 1987. Aspects of anticoagulant action: A review of the pharmacology, metabolism and toxicology of warfarin and congeners. Drug Metab. Drug Interact. 5: 225-272.
22. Tajima T, Kawashima H, Ogo T, Miyao K. 1971a. Protective effect of menaquinone-4 (K2) against fatal hemorrhage caused by coumarin. Nippon Yakurigaku Zasshi 67: 406-411.
23. Tajima T, Kawashima H, Ogo T, Miyao K. 1971b. Preventive effect of menaquinone-4 (K2) on hypoprothrombinemia caused by dicumarol. Nippon Yakurigaku Zasshi 67: 419-430.
24. Thijssen HHW. 1987. Warfarin resistance. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin. Biochem. Pharmacol. 36: 2753-2757.
25. Tischler M, Fieser LF, Wendler NL. 1940. Hydro, oxido and other derivatives of vitamin K1 and related compounds. J. Am. Chem. Soc. 62: 2866-2871.
26. Uchida O, Naito K, Yasuhara K, Ohba S, Sato C, Shimonuri S, Kobayashi K, Tobe M. 1985. Studies on the acute oral toxicity of dehydroacetic acid, sorbic acid and their combination compound in rats. Eisei Shikenjo Hokoku 103: 166-171.